Cowabunga! 🌊 Riding the Metastatic Breast Cancer Wave 🏄🏻‍♂️🤙🏻 from #ESMO26

Armando Orlandi· @ArmandOrlandi · X·2026-10-23 20:03· 2 天前评分70

正文 · 原文

APEX-Breast01: biparatopic HER2 antibody-drug conjugate TQB2102 vs chemo in HER2-low disease.
Progression-free survival 16.4 vs 5.5 mo.

New ADC, same ~0.3 hazard ratio. Time for head-to-head trials.

@OncoAlert @Larvol

294 浏览 · 5 赞 · 5 转发 · 0 回复

会议摘要

LBA27按 Proffered paper 1: Breast cancer, early and advanced stage 对上

APEX-Breast01: TQB2102 versus chemotherapy in HER2-low recurrent or metastatic breast cancer (r/m BC) - Results from a randomized phase 3 study

来源：Armando Orlandi · x.com